Radionuclide probes for molecular imaging of pancreatic beta-cells

Advanced Drug Delivery Reviews

Volumn 62, Issue 11, 2010, Pages 1125-1138

  Wu, Zhanhong ^a   Kandeel, Fouad ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

GLP 1 receptor; Neural imaging probes; Pancreatic beta cell imaging; PET; Radiolabeled antibody; Reporter gene; Saccharides; SPECT; Sulfonylurea receptor

Indexed keywords

BETA CELL; GLP-1 RECEPTOR; NEURAL IMAGING PROBES; PET; RADIOLABELED ANTIBODY; REPORTER GENE; SACCHARIDES; SPECT; SULFONYLUREA RECEPTORS;

ANTIBODIES; CELL CULTURE; CELL PROLIFERATION; DRUG PRODUCTS; GENES; PROBES; RESONANCE; SUGARS; TOXICITY;

MAGNETIC RESONANCE IMAGING;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 3,4 DIHYDROXY 6 FLUOROPHENYLALANINE F 18; 4 FLUOROBENZYLTROZAMICOL F 18; 9 (4 FLUORO 3 [HYDROXYMETHYL]BUTYL)GUANINE F 18; 9 FLUOROPROPYL DIHYDROTETRABENZENE F 18; CARBON 11; COPPER 64; DIHYDROTETRABENZENE C 11; EXENDIN 4; EXENDIN[9-39] F 18; FALLYPRIDE F 18; FIALURIDINE I 123; FIALURIDINE I 131; FLUORODEOXYGLUCOSE F 18; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MANNOHEPTULOSE; MONOCLONAL ANTIBODY I 125; MONOCLONAL ANTIBODY IN 111; PENTETIC ACID; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; REPAGLINIDE; REPAGLINIDE C 11; REPAGLINIDE F 18; SULFONYLUREA; SULFONYLUREA RECEPTOR; TOLBUTAMIDE; TROPOLONE IN 111; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELL POPULATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; ISOTOPE LABELING; MOLECULAR IMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; CELL TRACKING; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; HUMANS; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS TRANSPLANTATION; MOLECULAR IMAGING; MOLECULAR STRUCTURE; RADIOISOTOPES;

EID: 78649325301     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.09.006     Document Type: Review

References (122)

1. Kashiwagi A. General concept and pathophysiological mechanisms of progression of macrovascular complications in diabetes. Nippon Rinsho 2010, 68:777-787.
2. Resl M., Clodi M. Diabetes and cardiovascular complications. Wien. Med. Wochenschr. 2010, 160:3-7.
3. Cheung N., Mitchell P., Wong T.Y. Diabetic retinopathy. Lancet 2010, 376:124-136.
4. Lora C.M., Daviglus M.L., Kusek J.W., Porter A., Ricardo A.C., Go A.S., Lash J.P. Chronic kidney disease in United States Hispanics: a growing public health problem. Ethn. Dis. 2009, 19:466-472.
5. Fazeli S.A. Neuroprotection in diabetic encephalopathy. Neurodegener. Dis. 2009, 6:213-218.
6. Leoni L., Roman B.B. MR imaging of pancreatic islets: tracking isolation, transplantation and function. Curr. Pharm. Des. 2010, 16:1582-1594.
7. Medarova Z., Moore A. MRI as a tool to monitor islet transplantation. Nat. Rev. 2009, 5:444-452.
8. Medarova Z., Moore A. MRI in diabetes: first results. AJR Am. J. Roentgenol. 2009, 193:295-303.
9. Marzola P., Longoni B., Szilagyi E., Merigo F., Nicolato E., Fiorini S., Paoli G.T., Benati D., Mosca F., Sbarbati A. In vivo visualization of transplanted pancreatic islets by MRI: comparison between in vivo, histological and electron microscopy findings. Contrast Media Mol. Imaging 2009, 4:135-142.
10. Tai J.H., Foster P., Rosales A., Feng B., Hasilo C., Martinez V., Ramadan S., Snir J., Melling C.W., Dhanvantari S., Rutt B., White D.J. Imaging islets labeled with magnetic nanoparticles at 1.5Tesla. Diabetes 2006, 55:2931-2938.
11. Evgenov N.V., Medarova Z., Dai G., Bonner-Weir S., Moore A. In vivo imaging of islet transplantation. Nat. Med. 2006, 12:144-148.
12. Virostko J., Radhika A., Poffenberger G., Chen Z., Brissova M., Gilchrist J., Coleman B., Gannon M., Jansen E.D., Powers A.C. Bioluminescence imaging in mouse models quantifies beta cell mass in the pancreas and after islet transplantation. Mol. Imaging Biol. 2010, 12:42-53.
13. Roth D.J., Jansen E.D., Powers A.C., Wang T.G. A novel method of monitoring response to islet transplantation: bioluminescent imaging of an NF-?B transgenic mouse model. Transplantation 2006, 81:1185-1190.
14. Villalobos C., Nadal A., Nunez L., Quesada I., Chamero P., Alonso M.T., Garcia-Sancho J. Bioluminescence imaging of nuclear calcium oscillations in intact pancreatic islets of Langerhans from the mouse. Cell Calcium 2005, 38:131-139.
15. Young A.A., Carlo P., Smith P., Wolfe-Lopez D., Pittner R., Wang M.-W., Rink T. Evidence for release of free glucose from muscle during amylin-induced glycogenolysis in rats. FEBS Lett. 1993, 334:317-321.
16. 18F]fluoro-d-glucose in hyperglycemic rats. Int. J. Mol. Med. 2000, 6:549-552.
17. 18F]fluoro-d-glucose in control and diabetic rats. Int. J. Mol. Med. 2000, 5:525-532.
18. Malaisse W.J. On the track to the beta-cell. Diabetologia 2001, 44:393-406.
19. Prince H.M., Wall D.M., Ritchie D., Honemann D., Harrrison S., Quach H., Thompson M., Hicks R., Lau E., Davison J., Loudovaris M., Moloney J., Loveland B., Bartholeyns J., Katsifis A., Mileshkin L. In vivo tracking of dendritic cells in patients with multiple myeloma. J. Immunother. 2008, 31:166-179.
20. 18F]FDG-labeled natural killer cells to HER2/neu-positive tumors. Nucl. Med. Biol. 2008, 35:579-588.
21. Ritchie D., Mileshkin L., Wall D., Bartholeyns J., Thompson M., Coverdale J., Lau E., Wong J., Eu P., Hicks R.J., Prince H.M. In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer Immunol. Immunother. 2007, 56:155-163.
22. 18F-FDG-labeled progenitor cell therapy for acute myocardial infarction. J. Nucl. Med. 2007, 48:1708-1714.
23. Beeres S.L., Bengel F.M., Bartunek J., Atsma D.E., Hill J.M., Vanderheyden M., Penicka M., Schalij M.J., Wijns W., Bax J.J. Role of imaging in cardiac stem cell therapy. J. Am. Coll. Cardiol. 2007, 49:1137-1148.
24. Toso C., Zaidi H., Morel P., Armanet M., Andres A., Pernin N., Baertschiger R., Slosman D., Buhler L.H., Bosco D., Berney T. Positron-emission tomography imaging of early events after transplantation of islets of Langerhans. Transplantation 2005, 79:353-355.
25. Eriksson O., Eich T., Sundin A., Tibell A., Tufveson G., Andersson H., Felldin M., Foss A., Kyllonen L., Langstrom B., Nilsson B., Korsgren O., Lundgren T. Positron emission tomography in clinical islet transplantation. Am. J. Transplant. 2009, 9:2816-2824.
26. 3H] mannoheptulose. Cell Biochem. Funct. 2001, 19:171-179.
27. Crenier L., Courtois P., Malaisse W.J. Uptake of tritiated d-mannoheptulose by liver, pancreatic exocrine and endocrine cells. Int. J. Mol. Med. 2001, 8:155-157.
28. 3H]mannoheptulose. Am. J. Physiol. 2001, 281:E298-E303.
29. 3H]mannoheptulose. Int. J. Mol. Med. 2001, 7:405-406.
30. Ramirez R., Rasschaert J., Laghmich A., Louchami K., Nadi A.B., Jijakli H., Kadiata M.M., Sener A., Malaisse W.J. Uptake of d-mannoheptulose by normal and tumoral pancreatic islet cells. Int. J. Mol. Med. 2001, 7:631-638.
31. 125I]iodo-d-mannoheptulose by different cell types: in vitro and in vivo experiments. Int. J. Mol. Med. 2001, 7:495-500.
32. Bernal-Mizrachi E., Cras-Meneur C., Ohsugi M., Permutt M.A. Gene expression profiling in islet biology and diabetes research. Diab./Metab. Res. Rev. 2003, 19:32-42.
33. 11C]methoxy derivative of alpha-dihydrotetrabenazine: a radioligand for studying the vesicular monoamine transporter. Appl. Radiat. Isot. 1993, 44:1487-1489.
34. 11C]tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter. Nucl. Med. Biol. 1994, 21:151-156.
35. 11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J. Cereb. Blood Flow Metab. 1996, 16:1288-1299.
36. Maffei A., Liu Z., Witkowski P., Moschella F., Del Pozzo G., Liu E., Herold K., Winchester R.J., Hardy M.A., Harris P.E. Identification of tissue-restricted transcripts in human islets. Endocrinology 2004, 145:4513-4521.
37. Anlauf M., Eissele R., Schafer M.K., Eiden L.E., Arnold R., Pauser U., Kloppel G., Weihe E. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J. Histochem. Cytochem. 2003, 51:1027-1040.
38. 11C]DTBZ. Nucl. Med. Biol. 2006, 33:855-864.
39. Souza F., Simpson N., Raffo A., Saxena C., Maffei A., Hardy M., Kilbourn M., Goland R., Leibel R., Mann J.J., Van Heertum R., Harris P.E. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J. Clin. Invest. 2006, 116:1506-1513.
40. Souza F., Freeby M., Hultman K., Simpson N., Herron A., Witkowsky P., Liu E., Maffei A., Harris P.E. Current progress in non-invasive imaging of beta cell mass of the endocrine pancreas. Curr. Med. Chem. 2006, 13:2761-2773.
41. 11C]-dihydrotetrabenazine imaging of baboons: biodistribution and human radiation dosimetry estimates. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:790-797.
42. Harris P.E., Ferrara C., Barba P., Polito T., Freeby M., Maffei A. VMAT2 gene expression and function as it applies to imaging beta-cell mass. J. Mol. Med. 2008, 86:5-16.
43. Freeby M., Goland R., Ichise M., Maffei A., Leibel R., Harris P. VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease. Diab. Obes. Metab. 2008, 10(Suppl 4):98-108.
44. Fagerholm V., Mikkola K.K., Ishizu T., Arponen E., Kauhanen S., Nagren K., Solin O., Nuutila P., Haaparanta M. Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J. Nucl. Med. 2010, 51:1439-1446.
45. 11C] dihydrotetrabenazine positron emission tomography scanning in assessing beta-cell performance after sleeve gastrectomy and duodenal-jejunal bypass. Surgery 2010, 147:303-309.
46. 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J. Nucl. Med. 2008, 49:1171-1176.
47. 18F epoxide derivative of tetrabenazine. Nucl. Med. Biol. 2008, 35:825-837.
48. 18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. Nucl. Med. Biol. 2010, 37:357-363.
49. 18F]4-fluorobenzyltrozamicol. Eur. J. Nucl. Med. Mol. Imaging 2004, 31:258-260.
50. Clark P.B., Plaza M.J., Kraas J., Burbank N., Elster A.W., Garg P., Garg S., Gage H.D., Calles-Escandon J., Wagner J.D., Morton K. Dual radiotracer analysis of cholinergic neuronal changes in prediabetic mouse pancreas. Diab. Technol. Ther. 2009, 11:107-111.
51. 18F]fluorobenzyltrozamicol positron emission tomography. Diab. Technol. Ther. 2009, 11:451-455.
52. Sweet I.R., Cook D.L., Lernmark A., Greenbaum C.J., Wallen A.R., Marcum E.S., Stekhova S.A., Krohn K.A. Systematic screening of potential beta-cell imaging agents. Biochem. Biophys. Res. Commun. 2004, 314:976-983.
53. Lindstrom P., Sehlin J. Aromatic amino acids and pancreatic islet function: a comparison of l-tryptophan and l-5-hydroxytryptophan. Mol. Cell. Endocrinol. 1986, 48:121-126.
54. Borelli M.I., Villar M.J., Orezzoli A., Gagliardino J.J. Presence of DOPA decarboxylase and its localisation in adult rat pancreatic islet cells. Diabetes Metab. 1997, 23:161-163.
55. Kauhanen S., Seppanen M., Minn H., Nuutila P. Clinical PET imaging of insulinoma and beta-cell hyperplasia. Curr. Pharm. Des. 2010, [Epub ahead of print].
56. 18F-FDOPA: a multiple-target molecule. J. Nucl. Med. 2009, 50:1915-1918.
57. 18F-fluoro-l-DOPA PET in the preoperative localization of focal lesions in congenital hyperinsulinism. Radiology 2009, 253:216-222.
58. 18F]fluoro-l-DOPA positron emission tomography-computed tomography for surgery in focal congenital hyperinsulinism. J. Clin. Endocrinol. Metab. 2008, 93:869-875.
59. 18F]Fluoro-l-dopa PET/CT in congenital hyperinsulinism. J. Comput. Assist. Tomogr. 2007, 31:770-772.
60. 18F]fluoro-l-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:2120-2128.
61. 18F-DOPA) positron emission tomography as a tool to localize an insulinoma or ?-cell hyperplasia in adult patients. J. Clin. Endocrinol. Metab. 2007, 92:1237-1244.
62. 18F-fluorodopa PET scan. J. Pediatr. 2007, 150:140-145.
63. 18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J. Clin. Endocrinol. Metab. 2007, 92:4706-4711.
64. 18F-fluoro-l-DOPA. J. Nucl. Med. 2005, 46:560-566.
65. Mukherjee J., Yang Z.Y., Das M.K., Brown T. Fluorinated benzamide neuroleptics-III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl. Med. Biol. 1995, 22:283-296.
66. 18F-Fallypride PET to monitor pancreatic beta cell loss in diabetes mellitus. J. Nucl. Med. Meet. Abstr. 2009, 50:1947.
67. Garcia A., Sevrioukov E., Constantinescu C., Pan M.-L., Chandy K.G., Mukherjee J. Dual probe microPET imaging of rodent pancreas. J. Nucl. Med. Meet. Abstr. 2010, 51:88.
68. Ashcroft F.M., Rorsman P. Electrophysiology of the pancreatic beta-cell. Prog. Biophys. Mol. Biol. 1989, 54:87-143.
69. Aguilar-Bryan L., Clement J.P.t., Gonzalez G., Kunjilwar K., Babenko A., Bryan J. Toward understanding the assembly and structure of KATP channels. Physiol. Rev. 1998, 78:227-245.
70. Lebovitz H.E., Feinglos M.N. Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness. Diab. Care 1978, 1:189-198.
71. Panten U., Schwanstecher M., Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp. Clin. Endocrinol. Diab. 1996, 104:1-9.
72. Groop L. Metabolic effects of sulfonylurea drugs. A review. Ann. Clin. Res. 1983, 15(Suppl 37):16-20.
73. Sturgess N.C., Ashford M.L., Cook D.L., Hales C.N. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 1985, 2:474-475.
74. Schwanstecher M., Schwanstecher C., Dickel C., Chudziak F., Moshiri A., Panten U. Location of the sulphonylurea receptor at the cytoplasmic face of the beta-cell membrane. Br. J. Pharmacol. 1994, 113:903-911.
75. Meyer M., Chudziak F., Schwanstecher C., Schwanstecher M., Panten U. Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes. Br. J. Pharmacol. 1999, 128:27-34.
76. Niki I., Welsh M., Berggren P.O., Hubbard P., Ashcroft S.J. Characterization of the solubilized glibenclamide receptor in a hamster pancreatic beta-cell line, HIT T15. Biochem. J. 1991, 277(Pt 3):619-624.
77. Gaines K.L., Hamilton S., Boyd A.E. Characterization of the sulfonylurea receptor on beta cell membranes. J. Biol. Chem. 1988, 263:2589-2592.
78. + channel in insulin-secreting cells. J. Biol. Chem. 1987, 262:15840-15844.
79. Aguilar-Bryan L., Nichols C.G., Rajan A.S., Parker C., Bryan J. Co-expression of sulfonylurea receptors and KATP channels in hamster insulinoma tumor (HIT) cells. Evidence for direct association of the receptor with the channel. J. Biol. Chem. 1992, 267:14934-14940.
80. Hoekfelt B., Joensson A. Hypoglycemic activity in relation to chemical structure of potential oral antidiabetic substances. I. 1-Sulfonyl-3-alkylureas. J. Med. Pharm. Chem. 1962, 51:231-239.
81. Grace G.S., Ralf S., Chyng-Yann S., Abass A.A. Synthesis of fluorine-18 labeled sulfonureas as beta-cell imaging agents. J. Labelled Comp. Radiopharm. 2001, 44:127-139.
82. Schmitz A., Shiue C.Y., Feng Q., Shiue G.G., Deng S., Pourdehnad M.T., Schirrmacher R., Vatamaniuk M., Doliba N., Matschinsky F., Wolf B., Rosch F., Naji A., Alavi A.A. Synthesis and evaluation of fluorine-18 labeled glyburide analogs as beta-cell imaging agents. Nucl. Med. Biol. 2004, 31:483-491.
83. 18F]fluoroethoxy)benzenesulfonyl)-3-butyl urea: a potential ?-cell imaging agent. J. Labelled Comp. Radiopharm. 2002, 45:763-774.
84. Schneider S., Feilen P.J., Schreckenberger M., Schwanstecher M., Schwanstecher C., Buchholz H.G., Thews O., Oberholzer K., Korobeynikov A., Bauman A., Comagic S., Piel M., Schirrmacher E., Shiue C.Y., Alavi A.A., Bartenstein P., Rosch F., Weber M.M., Klein H.H., Schirrmacher R. In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans. Exp. Clin. Endocrinol. Diab. 2005, 113:388-395.
85. Schottelius M., Wester H.J., Reubi J.C., Senekowitsch-Schmidtke R., Schwaiger M. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. Bioconjug. Chem. 2002, 13:1021-1030.
86. Schneider S., Ueberberg S., Korobeynikov A., Schechinger W., Schwanstecher C., Schwanstecher M., Klein H.H., Schirrmacher E. Synthesis and evaluation of a glibenclamide glucose-conjugate: a potential new lead compound for substituted glibenclamide derivatives as islet imaging agents. Regul. Pept. 2007, 139:122-127.
87. Fuhlendorff J., Rorsman P., Kofod H., Brand C.L., Rolin B., MacKay P., Shymko R., Carr R.D. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998, 47:345-351.
88. 18F]repaglinide): a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography (PET). Nucl. Med. Biol. 2004, 31:639-647.
89. 11C]methoxy-repaglinide): a potential beta-cell imaging agent. Bioorg. Med. Chem. Lett. 2004, 14:5205-5209.
90. 18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl. Med. Biol. 1998, 25:175-180.
91. 18F]fluoro-3-hydroxymethylbutyl)guanine for in vivo measurement of suicide gene expression with PET. J. Nucl. Med. 2001, 42:1682-1690.
92. Tjuvajev J.G., Doubrovin M., Akhurst T., Cai S., Balatoni J., Alauddin M.M., Finn R., Bornmann W., Thaler H., Conti P.S., Blasberg R.G. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J. Nucl. Med. 2002, 43:1072-1083.
93. Alauddin M.M., Shahinian A., Gordon E.M., Conti P.S. Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model. Mol. Imaging 2004, 3:76-84.
94. Buursma A.R., Rutgers V., Hospers G.A., Mulder N.H., Vaalburg W., de Vries E.F. 18F-FEAU as a radiotracer for herpes simplex virus thymidine kinase gene expression: in-vitro comparison with other PET tracers. Nucl. Med. Commun. 2006, 27:25-30.
95. Yaghoubi S.S., Couto M.A., Chen C.C., Polavaram L., Cui G., Sen L., Gambhir S.S. Preclinical safety evaluation of 18F-FHBG: a PET reporter probe for imaging herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk's expression. J. Nucl. Med. 2006, 47:706-715.
96. Likar Y., Dobrenkov K., Olszewska M., Vider E., Shenker L., Cai S., Pillarsetty N., Hricak H., Ponomarev V. A new acycloguanosine-specific supermutant of herpes simplex virus type 1 thymidine kinase suitable for PET imaging and suicide gene therapy for potential use in patients treated with pyrimidine-based cytotoxic drugs. J. Nucl. Med. 2008, 49:713-720.
97. Lu Y., Dang H., Middleton B., Campbell-Thompson M., Atkinson M.A., Gambhir S.S., Tian J., Kaufman D.L. Long-term monitoring of transplanted islets using positron emission tomography. Mol. Ther. 2006, 14:851-856.
98. Lu Y., Dang H., Middleton B., Zhang Z., Washburn L., Stout D.B., Campbell-Thompson M., Atkinson M.A., Phelps M., Gambhir S.S., Tian J., Kaufman D.L. Noninvasive imaging of islet grafts using positron-emission tomography. Proc. Natl Acad. Sci. USA 2006, 103:11294-11299.
99. Kim S.J., Doudet D.J., Studenov A.R., Nian C., Ruth T.J., Gambhir S.S., McIntosh C.H. Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival. Nat. Med. 2006, 12:1423-1428.
100. Tai J.H., Nguyen B., Wells R.G., Kovacs M.S., McGirr R., Prato F.S., Morgan T.G., Dhanvantari S. Imaging of gene expression in live pancreatic islet cell lines using dual-isotope SPECT. J. Nucl. Med. 2008, 49:94-102.
101. Holst J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007, 87:1409-1439.
102. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
103. Goke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 1993, 268:19650-19655.
104. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 1992, 267:7402-7405.
105. Ahn J.-M., Murage E.N., Lin M., Lo S.-T., Sun X. Highly constrained GLP-1 analogues as non-invasive PET Imaging Probes for Pancreatic Beta-Cells. 70th ADA Scientific Sessions abstract 2010.
106. Gotthardt M., Lalyko G., van Eerd-Vismale J., Keil B., Schurrat T., Hower M., Laverman P., Behr T.M., Boerman O.C., Goke B., Behe M. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul. Pept. 2006, 137:162-167.
107. Mukai E., Toyoda K., Kimura H., Kawashima H., Fujimoto H., Ueda M., Temma T., Hirao K., Nagakawa K., Saji H., Inagaki N. GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging. Biochem. Biophys. Res. Commun. 2009, 389:523-526.
108. Wang Y., Lim K., Normandin M., Zhao X., Cline G., Ding Y.-S. Synthesis and evaluation of F-18-exendin as a potential biomarker to measure pancreatic beta-cell mass. J. Nucl. Med. Meet. Abstr. 2010, 51:195.
109. Toyoda K., Kimura H., Mukai E., Ogama Y., Fujimoto H., Ueda M., Temma T., Kawashima H., Hirao K., Matsuda H., Nagakawa K., Saji H., Inagaki N. Non-Invasive PET Imaging of Pancreatic Islets Targeting Glucagon-Like Peptide-1 Receptors. 70th ADA Scientific Sessions abstract 2010.
110. Konidaris C., Simonson W., Michelsen B., Papadopoulos G.K. Specific monoclonal antibodies against the surface of rat islet beta cells. Cell Biol. Int. 2002, 26:817-828.
111. Ziegler B., Lucke S., Kohler E., Hehmke B., Schlosser M., Witt S., Besch W., Ziegler M. Monoclonal antibody-mediated cytotoxicity against rat beta cells detected in vitro does not cause beta-cell destruction in vivo. Diabetologia 1992, 35:608-613.
112. Buschard K., Brogren C.H., Ropke C., Rygaard J. Antigen expression of the pancreatic beta-cells is dependent on their functional state, as shown by a specific, BB rat monoclonal autoantibody IC2. APMIS 1988, 96:342-346.
113. 125I-labelled mouse monoclonal antibody directed against pancreatic B-cell surface ganglioside(s) in control and diabetic rats. Cell Biochem. Funct. 2001, 19:107-115.
114. Moore A., Bonner-Weir S., Weissleder R. Noninvasive in vivo measurement of beta-cell mass in mouse model of diabetes. Diabetes 2001, 50:2231-2236.
115. Hampe C.S., Wallen A.R., Schlosser M., Ziegler M., Sweet I.R. Quantitative evaluation of a monoclonal antibody and its fragment as potential markers for pancreatic beta cell mass. Exp. Clin. Endocrinol. Diab. 2005, 113:381-387.
116. Moldovan S., Atiya A., Adrian T.E., Kleinman R.M., Lloyd K., Olthoff K., Imagawa D., Shevlin L., Coy D., Walsh J., et al. Somatostatin inhibits B-cell secretion via a subtype-2 somatostatin receptor in the isolated perfused human pancreas. J. Surg. Res. 1995, 59:85-90.
117. Yang L., Berk S.C., Rohrer S.P., Mosley R.T., Guo L., Underwood D.J., Arison B.H., Birzin E.T., Hayes E.C., Mitra S.W., Parmar R.M., Cheng K., Wu T.J., Butler B.S., Foor F., Pasternak A., Pan Y., Silva M., Freidinger R.M., Smith R.G., Chapman K., Schaeffer J.M., Patchett A.A. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc. Natl Acad. Sci. USA 1998, 95:10836-10841.
118. Rohrer S.P., Birzin E.T., Mosley R.T., Berk S.C., Hutchins S.M., Shen D.M., Xiong Y., Hayes E.C., Parmar R.M., Foor F., Mitra S.W., Degrado S.J., Shu M., Klopp J.M., Cai S.J., Blake A., Chan W.W., Pasternak A., Yang L., Patchett A.A., Smith R.G., Chapman K.T., Schaeffer J.M. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998, 282:737-740.
119. Amartey J.K., Esguerra C., Al-Jammaz I., Parhar R.S., Al-Otaibi B. Synthesis and evaluation of radioiodinated substituted beta-naphthylalanine as a potential probe for pancreatic beta-cells imaging. Appl. Radiat. Isot. 2006, 64:769-777.
120. Barry M.A., Dower W.J., Johnston S.A. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat. Med. 1996, 2:299-305.
121. Samli K.N., McGuire M.J., Newgard C.B., Johnston S.A., Brown K.C. Peptide-mediated targeting of the islets of Langerhans. Diabetes 2005, 54:2103-2108.
122. Lin M., Lubag A., McGuire M.J., Seliounine S.Y., Tsyganov E.N., Antich P.P., Sherry A.D., Brown K.C., Sun X. Advances in molecular imaging of pancreatic beta cells. Front. Biosci. 2008, 13:4558-4575.